Immune response profiling in early rheumatoid arthritis: discovery of a novel interaction of treatment response with viral immunity

Table 2 Characteristics of exposure to DMARDs during follow up among 71 patients with early RA

Medication	Baseline		Follow up
Medication	Prior to baseline	Prescribed at baseline visit	Cumulative exposure	Taking at follow-up visit
Methotrexate	14 (20%)	49 (69%)	51 (72%)	50 (70%)
Hydroxychloroquine	8 (11%)	24 (34%)	44 (39%)	28 (39%)
Combination DMARD	5 (7%)	10 (14%)	17 (24%)	16 (23%)
Prednisone	16 (23%)	46 (65%)	49 (69%)	29 (41%)
Dose, mean ± SD		17.4 ± 14.2		6.7 ± 5.6
Median (minimum, maximum)		10.0 (5, 75)		5 (1, 25)

Medications prescribed at the baseline visit include initiation within 2 weeks after baseline. DMARD, disease-modifying antirheumatic drug.

ISSN: 1478-6362